Benutzer: Gast  Login
Titel:

TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status.

Dokumenttyp:
Journal Article
Autor(en):
Ben Khaled, Najib; Hammer, Katharina; Ye, Liangtao; Alnatsha, Ahmed; Widholz, Sebastian A; Piseddu, Ignazio; Sirtl, Simon; Schneider, Julia; Munker, Stefan; Mahajan, Ujjwal Mukund; Montero, Juan José; Griger, Joscha; Mayerle, Julia; Reiter, Florian P; De Toni, Enrico N
Abstract:
Chemotherapy, the standard treatment for pancreatic ductal adenocarcinoma (PDAC), has only a modest effect on the outcome of patients with late-stage disease. Investigations of the genetic features of PDAC have demonstrated a frequent occurrence of mutations in genes involved in homologous recombination (HR), especially in the breast cancer susceptibility gene 2 (BRCA2). Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, is approved as a maintenance treatment for patients with advanced PD...     »
Zeitschriftentitel:
Cancers (Basel)
Jahr:
2022
Band / Volume:
14
Heft / Issue:
21
Volltext / DOI:
doi:10.3390/cancers14215240
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/36358659
TUM Einrichtung:
Professur für Molekulare Onkologie und Funktionelle Genomik (Prof. Rad)
 BibTeX